Features
- Maintains undifferentiation of iPS/ES cells in 2D/3D culture.
- Removes differentiated iP/ES cells in 2D culture.
- Stabilizes ectoderm/mesoderm/endoderm and downstream differentiations.
- Demonstrated cardiomyocytes, pancreatic cells, lung cells, hepatocyte, RPE differentiations.
Background and Technology
| Regenerative medicine led by academia utilizing iPSC/ESC technologies have been reported for many indications. Those are realized by semi-manual cell culturing by skilled technicians. However, for wide-spread use of regenerative medicine by iPSC/ESC derived cells, establishment of low cost, high quality and largescale cell production protocol is crucial. A team of Osaka University, who has been tackling this issue, found that controlling cell junction force can ease the stress to the cells, maintain quality(undifferentiation), and guide differentiation by adding bHA at the biggening of standard differentiation protocols. bHA can be synthesized in E-coli expression system. |
 |
 |
Patents
Filed by Osaka University:
WO2014/104207, WO2015/199243, WO2018/117110, WO2023/149565, WO2023/149566.
Researcher
Professor, Masahiro Kino-oka, Department of Biotechnology, Osaka University
Expectations
- We are seeking companies who license and commercialize this technology.
- Cell therapy companies, CDMOs, reagent manufactures are welcome.
- Samples can be provided under MTA.
Project.KJ-00179